MARKET

PEN

PEN

Penumbra Inc
NYSE
236.67
+1.75
+0.74%
After Hours: 236.67 0 0.00% 16:20 03/01 EST
OPEN
234.72
PREV CLOSE
234.92
HIGH
239.68
LOW
232.53
VOLUME
279.12K
TURNOVER
0
52 WEEK HIGH
348.67
52 WEEK LOW
180.93
MARKET CAP
9.16B
P/E (TTM)
102.04
1D
5D
1M
3M
1Y
5Y
Piper Sandler cuts Inari to neutral; cites slowing growth, DOJ probe
Seeking Alpha · 1d ago
Analysts Offer Insights on Healthcare Companies: Penumbra (PEN), Jazz Pharmaceuticals (JAZZ) and Argenx Se (ARGX)
TipRanks · 2d ago
Penumbra Q4: Solid Is Not Good Enough
Penumbra, Inc. Focuses on removing clots and treating aneurysms in the neurovascular market. The company reported a 29% increase in sales in the fourth quarter. Despite solid growth and operating leverage, Penumbra valuations remain high as slower growth raises concerns.
Seeking Alpha · 5d ago
Weekly Report: what happened at PEN last week (0219-0223)?
Weekly Report · 6d ago
Buy Rating Justified by Penumbra’s Market Presence and Projected Growth
TipRanks · 6d ago
Noteworthy Friday Option Activity: ATMU, NAT, PEN
NASDAQ · 02/23 20:18
Why MercadoLibre Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
MercadoLibre shares dipped 9.6% to $1,643.30 on Friday. The company reported quarterly earnings of $3.25 per share. AXT, Inc. Shares surged 74.4% after the company reported better-than-expected fourth-quarter results.
Benzinga · 02/23 19:07
Penumbra cut to Hold at J.P. Morgan on first revenue miss
Penumbra cut to Hold at J.P. Morgan on first revenue miss in history. The medical device company's Q4 2023 revenue fell short of estimates. The miss is the company's first topline miss in its history. PEN's 2024 outlook implied 16% -20% revenue growth.
Seeking Alpha · 02/23 17:46
More
About PEN
Penumbra, Inc. is a global healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that focuses on medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. It has developed a product portfolio that includes seven product families within its major markets, in which its neuro products include Thrombectomy, Embolization, Access, and Neurosurgical Tools. Its vascular products include Thrombectomy and Embolization. The Company's immersive healthcare product is Immersive 3D Computer-based Technology Platform. The Company sells its products to hospitals and healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia.

Webull offers Penumbra Inc stock information, including NYSE: PEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PEN stock methods without spending real money on the virtual paper trading platform.